SRT3025

Phase 1Small molecule

GSK

SRT3025 is one of 25 small molecule programs targeting Metabolic Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metabolic DiseaseActive, not recruiting

Metabolic DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

27 competitors in Metabolic Disease

#DrugCompanyPhaseTrials

Tivicay

GSK

Approved

1 2

Onglyza

Farxiga

Avandia

Alnylam Pharmaceuticals

Approved

—5

Altoprev

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Tricor

Glucophage

Crestor

1 9

Neoral

Novartis

Phase 2

1 10

Medrol

Pfizer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metabolic Disease1 trial

A Study in Healthy Male Volunteers to Investigate Different Doses of a New Drug for the Treatment of Metabolic Diseases

Completed·—·Phase 1·NCT01340911·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SRT3025. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SRT3025 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SRT3025. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: GSK

SRT3025

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metabolic Disease1 trial

References

Drug Info

Quick Facts

Related News